One year results of coronary bifurcation revascularization with the re-POT provisional sequential technique. The CABRIOLET registry.

Coronary bifurcation Provisional stenting Proximal optimization technique

Journal

International journal of cardiology
ISSN: 1874-1754
Titre abrégé: Int J Cardiol
Pays: Netherlands
ID NLM: 8200291

Informations de publication

Date de publication:
03 Dec 2023
Historique:
received: 28 08 2023
revised: 18 11 2023
accepted: 30 11 2023
pubmed: 5 12 2023
medline: 5 12 2023
entrez: 4 12 2023
Statut: aheadofprint

Résumé

Re-POT (proximal optimization technique (POT)) is a simple provisional sequential technique for percutaneous coronary bifurcation revascularization with better arterial geometry respect compared to classical techniques. Re-POT has demonstrated excellent mechanical and short-term clinical results. The multicenter CABRIOLET registry (NCT03550196) evaluate the long-term clinical benefit of the re-POT sequence in non-selected patients. All consecutive patients presenting a coronary bifurcation lesion for which provisional stenting was indicated were included in 5 european centers. Re-POT strategy was systematically attempted. The primary endpoint was target lesion failure (TLF), comprising cardiac death, myocardial infarction, stent thrombosis and target lesion revascularization (TLR) at 12 months' follow-up. The secondary endpoints were the individual components of the primary endpoint, all-cause death, target vessel failure (TVF) and target vessel revascularization (TVR). Complex bifurcation was defined as Medina 0.1.1 or 1.1.1. A total of 500 patients aged 67.7 ± 11.7 years, 78.4% male, were included from 2015 to 2019, 174 of whom (34.8%) were considered having complex bifurcation lesions. Bifurcations involved the left main in 35.2% of cases. The full re-POT sequence was systematically performed in all cases. At 1 year, TLF was 2.0% (1.7% in complex vs. 2.1% in non-complex bifurcation; p = NS), and TLR was 1.6%, (1.1% vs. 1.8% respectively; p = NS). TVF and TVR rates were 3.2% and 2.8%. On multivariate analysis, only multivessel disease was predictive of TLF at 1 year (OR = 1.66 (1.09-2.53), p = 0.02). In this large prospective all-comer registry, provisional stenting with re-POT technique appeared safe and effective at 1 year, without anatomical bifurcation restriction.

Sections du résumé

BACKGROUND BACKGROUND
Re-POT (proximal optimization technique (POT)) is a simple provisional sequential technique for percutaneous coronary bifurcation revascularization with better arterial geometry respect compared to classical techniques. Re-POT has demonstrated excellent mechanical and short-term clinical results. The multicenter CABRIOLET registry (NCT03550196) evaluate the long-term clinical benefit of the re-POT sequence in non-selected patients.
METHODS METHODS
All consecutive patients presenting a coronary bifurcation lesion for which provisional stenting was indicated were included in 5 european centers. Re-POT strategy was systematically attempted. The primary endpoint was target lesion failure (TLF), comprising cardiac death, myocardial infarction, stent thrombosis and target lesion revascularization (TLR) at 12 months' follow-up. The secondary endpoints were the individual components of the primary endpoint, all-cause death, target vessel failure (TVF) and target vessel revascularization (TVR). Complex bifurcation was defined as Medina 0.1.1 or 1.1.1.
RESULTS RESULTS
A total of 500 patients aged 67.7 ± 11.7 years, 78.4% male, were included from 2015 to 2019, 174 of whom (34.8%) were considered having complex bifurcation lesions. Bifurcations involved the left main in 35.2% of cases. The full re-POT sequence was systematically performed in all cases. At 1 year, TLF was 2.0% (1.7% in complex vs. 2.1% in non-complex bifurcation; p = NS), and TLR was 1.6%, (1.1% vs. 1.8% respectively; p = NS). TVF and TVR rates were 3.2% and 2.8%. On multivariate analysis, only multivessel disease was predictive of TLF at 1 year (OR = 1.66 (1.09-2.53), p = 0.02).
CONCLUSIONS CONCLUSIONS
In this large prospective all-comer registry, provisional stenting with re-POT technique appeared safe and effective at 1 year, without anatomical bifurcation restriction.

Identifiants

pubmed: 38048882
pii: S0167-5273(23)01766-7
doi: 10.1016/j.ijcard.2023.131632
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

131632

Informations de copyright

Copyright © 2023 Elsevier B.V. All rights reserved.

Auteurs

François Dérimay (F)

Department of Interventional Cardiology, Cardiovascular Hospital, Hospices Civils de Lyon, Lyon, France; INSERM U1060, CarMeN Laboratory, Université de Lyon, Lyon, France. Electronic address: fderimay@hotmail.fr.

Adel Aminian (A)

Cardiology Department, Centre Hospitalier Universitaire de Charleroi, Charleroi, Belgium.

Benoit Lattuca (B)

ACTION Study Group, Cardiology Department, Centre Hospitalier Universitaire de Nimes, Nimes, France.

Géraud Souteyrand (G)

Cardiology Department, CHU Clermont-Ferrand, Clermont-Ferrand, France.

Luc Maillard (L)

GCS ES Axium Rambot, Aix-en-Provence, France.

Sean Alvain (S)

Department of Interventional Cardiology, Cardiovascular Hospital, Hospices Civils de Lyon, Lyon, France.

Guillaume Cayla (G)

ACTION Study Group, Cardiology Department, Centre Hospitalier Universitaire de Nimes, Nimes, France.

Pascal Motreff (P)

Cardiology Department, CHU Clermont-Ferrand, Clermont-Ferrand, France.

Thomas Bochaton (T)

INSERM U1060, CarMeN Laboratory, Université de Lyon, Lyon, France; Department of Intensive Cardiac Care, Cardiovascular Hospital, Hospices Civils de Lyon, Bron, France.

Ahmad Hayek (A)

INSERM U1060, CarMeN Laboratory, Université de Lyon, Lyon, France; Department of Intensive Cardiac Care, Cardiovascular Hospital, Hospices Civils de Lyon, Bron, France.

Gilles Rioufol (G)

Department of Interventional Cardiology, Cardiovascular Hospital, Hospices Civils de Lyon, Lyon, France; INSERM U1060, CarMeN Laboratory, Université de Lyon, Lyon, France.

Gérard Finet (G)

Department of Interventional Cardiology, Cardiovascular Hospital, Hospices Civils de Lyon, Lyon, France; INSERM U1060, CarMeN Laboratory, Université de Lyon, Lyon, France.

Classifications MeSH